UK regulators green-light early access to Santhera’s Raxone for Duchenne MD
Santhera Pharmaceuticals saw its shares {SIX: $SANN} jump 16% today after the Swiss biotech reported that UK regulators will provide early access to their drug Raxone (idebenone) for use in fighting symptoms of Duchenne muscular dystrophy.
British regulators say that the data indicate that this drug can provide a longterm benefit for boys experiencing respiratory decline and not on or able to take glucocorticoids. They also endorsed the safety profile of the drug.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
